William Johnston Scott

USPTO Granted Patents = 49 (Patent Applications = 3)

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 21 (Patent Applications = 15)

Average Co-Inventor Count = 4.0

ph-index = 17

Forward Citations = 795(Granted Patents)

Location History:

Monterey Park, CA (US) (1978)
Costa Mesa, CA (US) (1979)
Phoenix, AZ (US) (2002)
Silver City, NM (US) (2003)
Guildford, CT (US) (2011)
Guilford, CT (US) (1999 - 2020)
Mesa, AZ (US) (2021 - 2024)

Company Filing History:

Bayer Intellectual Property Gmbh

patents

8 out of 70

Bayer Pharmaceuticals Corporation

Bayer Pharma Aktiengesellschaft

patents

6. 1 out of 12,160

Bayer Aktiengesellschaft

patents

7. 1 out of 1

Bayer Pharma Aktiengesselschaft

patent

8. 5 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1978-2024

Loading Chart...

Areas of Expertise:

Cellular Phone Enclosure

Angiogenesis Inhibitors

Kinase Inhibitors

Hyper-Proliferative Disorders

Imidazopyridazines

Diphenyl Ureas

Pyridine Derivatives

Pharmaceutical Compositions

Cancer Treatment

Paint Strainer

Pipe Joining Connection

Solar Reflector Collector

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11901928 - Systems and methods for a cellular phone enclosure (2024-02-13),

2. 11146301 - Systems and methods for a cellular phone enclosure (2021-10-12),

3. 10653684 - Aryl ureas with angiogenisis inhibiting activity (2020-05-19),

4. 10130633 - Compounds (2018-11-20),

5. RE46856 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2018-05-21),

6. 9902727 - Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2018-02-27),

7. 9730943 - Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines (2017-08-15),

8. 9675616 - Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines (2017-06-13),

9. 9604989 - Imidazopyridazines as Akt kinase inhibitors (2017-03-28),

10. 9370517 - Substituted pyrazolopyrimidines as Akt kinase inhibitors (2016-06-21),

11. 9260435 - Substituted imidazopyrazines as Akt kinase inhibitors (2016-02-16),

12. 9206185 - Imidazopyridazines as Akt kinase inhibitors (2015-12-08),

13. 9199999 - Substituted imidazopyrazines (2015-12-01),

14. 9181188 - Aryl ureas as kinase inhibitors (2015-11-10),

15. 8975265 - Substituted imidazo[1,2-a]pyrimidines and —pyridines (2015-03-10),

Title: William Johnston Scott: Innovator in Angiogenesis Inhibition

Introduction

William Johnston Scott, an accomplished inventor located in Guilford, CT, holds an impressive portfolio of 43 patents. His extensive work primarily focuses on developments in the medical field, particularly concerning angiogenesis and its implications in treating diseases.

Latest Patents

Among Scott's latest patents is a pivotal invention related to aryl ureas with angiogenesis inhibiting activity. This innovative concept revolves around methods utilizing aryl ureas to combat diseases mediated by the VEGF-induced signal transduction pathway, which is characterized by abnormal angiogenesis or hyperpermeability processes. Another significant patent pertains to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides. This invention includes the preparation of these compounds for potential pharmaceutical applications, particularly in cancer treatment. The compounds outlined have varied structural elements, such as substituents represented by R and L groups, which play a crucial role in their therapeutic properties.

Career Highlights

Scott's career includes significant contributions while working with reputable organizations, notably Bayer Healthcare LLC and Bayer Intellectual Property GmbH. His role in these companies has facilitated the advancement of health-related innovations, driving forward the development of therapies that leverage his patented technologies.

Collaborations

Throughout his illustrious career, Scott has collaborated with esteemed coworkers, including Jacques P. Dumas and Jill E. Wood. These partnerships demonstrate the collaborative nature of innovation, where combining expertise can lead to groundbreaking developments in medical research and treatment methodologies.

Conclusion

William Johnston Scott's contributions to the field of angiogenesis inhibition exemplify the profound impact of innovative thinking on medical advancements. With a robust patent portfolio and a history of collaboration with leading professionals, Scott continues to play a significant role in shaping therapies aimed at combating diseases characterized by abnormal angiogenesis. His work stands as a testament to the importance of innovation in health and medicine.

This text is generated by artificial intelligence and may not be accurate.